Pure Global
NCT06272227

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial
Yonsei University·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sarcopenia
Drug/Device/Intervention
alfacalcidol
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Yonsei University
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 4
Start date
Feb 13, 2024
End date
Sep 01, 2025
Enrollment
340 participants
Primary outcome

Improvement in SPPB score of 0.5 or more compared to the control group

Summary

This study aims to investigate the potential improvement in muscle function, compared to the
 placebo group, through the concurrent administration of denosumab and alfacalcidol over a
 one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65
 and older. The study is planned as a double-blinded randomized controlled trial, intending to
 recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5
 or more compared to the control group.

ICD-10 classifications
Kaposi sarcomaHerniaTaeniasisTaenia saginata taeniasisDiaphragmatic hernia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06272227
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06272227 through Pure Global AI's free database. This Phase 4 trial is sponsored by Yonsei University and is currently Not yet recruiting. The study focuses on Sarcopenia. Target enrollment is 340 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.